Research programme: mRNA therapeutics - Vertex Pharmaceuticals/Moderna Therapeutics

Drug Profile

Research programme: mRNA therapeutics - Vertex Pharmaceuticals/Moderna Therapeutics

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator Moderna Therapeutics; Vertex Pharmaceuticals
  • Class RNA
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cystic fibrosis

Most Recent Events

  • 06 Jul 2016 Early research in Cystic fibrosis in USA (Parenteral)
  • 06 Jul 2016 Moderna Therapeutics and Vertex Pharmaceuticals agree to discover and develop mRNA therapeutics in USA for Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top